TABLE 1.

Baseline characteristics of study patients^a

	Ceftazidime-avibactam group (n = 105)	Meropenem-vaborbactam group (n = 26)	P value
No. of males (%)	58 (55.2)	12 (46.2)	0.41
Median age (yrs) (IQR)	62.0 (51.0–69.0)	57.5 (50.0–70.0)	0.68
Median weight (kg) (IQR)	75.9 (64.0–95.7)	82.5 (70.4–91.0)	0.50
Race
No. white (%)	77 (73.3)	19 (73.1)	0.58
No. African American (%)	24 (22.9)	5 (19.2)	0.58
No. Asian (%)	1 (0.9)	0	0.58
No. other (%)	3 (2.9)	2 (7.7)	0.58
No. of hospital-acquired infections (%)	65 (61.9)	13 (50.0)	0.27
No. of community-acquired infections (%)	40 (38.1)	13 (50.0)	0.27
No. with history of CRE infection or colonization (%)	24 (22.9)	7 (26.9)	0.66
Median Charlson comorbidity index (IQR)	5.0 (3.0–6.0)	5.0 (3.0–8.0)	0.65
No. of comorbidities (%)
Diabetes mellitus	49 (46.7)	13 (50.0)	0.76
Chronic kidney disease	33 (31.4)	9 (34.6)	0.76
Chronic respiratory disease	33 (31.4)	8 (30.8)	0.95
History of malignancy	23 (21.9)	5 (19.2)	0.77
Chronic liver disease	16 (15.2)	6 (23.1)	0.38
Human immunodeficiency virus	0	1 (3.9)	0.20
No. immunocompromised (%)	12 (11.4)	4 (15.4)	0.52
Severity of illness
No. with ICU status at time of positive culture (%)	58 (55.2)	17 (65.4)	0.35
Median APACHE II score (IQR)	26.0 (22.0–30.0)	27.0 (24.0–34.0)	0.19
No. with primary bacteremia (%)	7 (6.7)	1 (3.8)	0.75
No. with secondary bacteremia (%)	37 (35.2)	8 (30.8)	0.75
Urinary tract	13 (35.1)	1 (12.5)	0.43
Intra-abdominal	6 (16.2)	3 (37.5)	0.43
Respiratory	7 (18.9)	2 (25.0)	0.43
Catheter-associated	5 (13.5)	0	0.43
Soft tissue	2 (5.4)	1 (12.5)	0.43
Other	4 (10.8)	1 (12.5)	0.43
No. with nonbloodstream infections (%)	61 (58.1)	17 (65.4)	0.75
Respiratory	30 (49.2)	10 (58.8)	0.47
Soft tissue	18 (29.5)	2 (11.8)	0.47
Intra-abdominal	12 (19.7)	5 (29.4)	0.47
Other	1 (1.6)	0	0.47

^aCRE, carbapenem-resistant Enterobacteriaceae; ICU, intensive care unit; IQR, interquartile range; KPC, Klebsiella pneumoniae carbapenemase.